ArticleBlood2024

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.

Despoina Papazoglou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.